Concert Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals (europe) Limited

Other

Sun Pharmaceutical Industries Limited

Merck + Co., Inc.

Glaxo Wellcome Inc.

Roger D Tung

Scott L Harbeson

Govinda Rao Bhisetti

Julie Fields Liu

Mark Andrew Murcko

David D Deininger

Craig E Masse

Andrew Spaltenstein

Michael Robin Hale

Christopher Todd Baker

Adam J Morgan

Jeffrey O Saunders

Luc J Farmer

Eric Steven Furfine

Joshua S Boger

Istvan Kaldor

Harold V Meyers

Andreas Peter Termin

Esther Martinborough

Timothy Donald Neubert

Dean Wilson

Yulian Zhang

Benjamin John Petzoldt

Francesco Gerald Salituro

David M Armistead

John E Cochran

Bhaumik Pandya

Wieslaw Mieczylaw Kazmierski

Peter D J Grootenhuis

Stephen Colin Price

Jesus E Gonzalez, Iii

Jesus Arturo Gonzalez

Nicole Hilgraf

Lev Tyler Dewey Fanning

I Robert Silverman

Dario Doller

Nicole Zimmerman

Vicente Samano

John Franklin Miller

Christopher L Brummel

Wayne Carl Schairer

David A Armistead

Biqin Li

Ian Robert Silverman

Robin David Wilkes

Ashley Nicholas Jarvis

Bigin Li

Mark G Bock

David J Lauffer

Daniel F Veber

Roger M Freidinger

Michael D Mullican

Peter D Williams

Peter Grootenhuis

Peter Diederik Jan Grootenhuis

Lev T D Fanning

Perry M Novak

Thomas E D'Ambra

Ronald George Sherrill

Adam Morgan

Michael Stephen Brieger

Lev Fanning

Michael Shin-San Su

John Mark O'Callaghan

Emile Al-Farhan

Mark Stuart Robertson

Keith Rodgers

Stephen John Rout

Hardew Singh

Stephen McGhie

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σreceptor agonist that also has NMDA antagonist activity.

Morphinan compounds

This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

Deuterated analogs of D-serine and uses thereof

This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

4-hydroxybutyric acid analogs

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a &#x3c3;receptor agonist that also has NMDA antagonist activity.

The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification, as well as pharmaceutical compositions comprising the same, and methods of using such compounds and compositions to inhibit at least one of Janus Kinase-1 and -2 and diseases associated with those kinases.

Deuterated baricitinib

The present invention in one embodiment provides a method of treating Leber's hereditary optic neuropathy, comprising administering to a subject in need of such treatment a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

Deuterated idebenone

This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

Deuterated CFTR potentiators

This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.

Deuterated CFTR modulators

This invention relates to novel deuterated forms of GFT-505, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are characterized by reduced PPAR-alpha and/or PPAR-delta activity.

Deuterated GFT-505

The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

Substituted xanthine derivatives

Growing community of inventors

Lexington, MA, United States of America

Roger D Tung